Skip to main content

Advertisement

SpringerLink
Log in

Natural-killer-stimulatory effect of combined low-dose interleukin-2 and interferon β in hairy-cell leukemia patients

  • Original Articles
  • IFNβ, IL-2, NK Cell Activity, Hairy-Cell Leukemia, IFNγ
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

The association of low doses of interleukin-2 (IL-2; 5 IU/ml) and interferon β (IFNβ; 10 IU/ml) induced an additive or synergic stimulatory effect on natural killer (NK) activity (32%) in peripheral blood samples from hairy-cell leukemia patients, both those with active disease and those in remission. The synergic NK stimulatory effect was more commonly found in samples from patients with active disease, while the additive effect was more frequent in the patients in remission. The IL-2/IFNβ combination provoked a nonadditive nonsynergic NK-stimulatory effect in a further 19.8% samples. The targets of the IL-2/IFNβ combination were typical NK cells, as shown by the fact that there was increased cytotoxicity (synergic, additive or nonadditive nonsynergic) against the K562, but not the Daudi cell line in peripheral blood mononuclear cell samples treated with the combination of the two cytokines. When CD16+/CD56+ or CD57+/CD16+/CD56+ cells were removed, the NK-stimulatory effect was lost. The fact that the NK-cell-enhancing activity of the IL-2/IFNβ combination was reduced when Percoll fractions 2 and 3 were used, but still persisted in 66% of tests, may have been due to cytotoxicity being higher in the untreated fractions 2 and 3 than in the untreated unfractionated samples. One of the factors responsible for the NK-stimulatory effect appears to be the capacity of the IL-2/IFNβ combination to trigger an increase in IFNγ synthesis. If similar experiments give like results in samples from patients suffering from other B-cell lymphoproliferative, or HIV-associated disorders, all of which are characterized by a deficiency in NK activity, it should be possible to use low-dose IL-2/IFNβ to treat these disorders and, perhaps, residual neoplastic disease without exposing the patient to undue toxicity. Further, by testing other combinations one should be able to identify the lowest IL-2 and IFNβ doses that would effectively boost the additive or synergic effect in a greater number of cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allison MAK, Jones SE, McGuffey P (1989) Phase II trial of outpatient interleukin-2 in malignant lymphoma chronic lymphocytic leukemia and solected solid tumors. J Clin Ontol 7: 75

    Google Scholar 

  2. Armitage P (1971) Regression and oorrelation. In: Statistical methods in medical research, 1st edn. Blackwell, Oxford, p 159

    Google Scholar 

  3. Berenbaum MC (1981) Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35: 269

    PubMed  Google Scholar 

  4. Brooks CG, Holscher M, Urdal D (1985) Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin 2, interferon, and specific antigen. J Immunol 135: 1145

    PubMed  Google Scholar 

  5. Cawley JC, Armitage RJ, Worman CP (1984) T cell subsets in hairy cell leukemia. Semin Oncol 11: 405

    PubMed  Google Scholar 

  6. Chen BP, Sondel PM (1986) Cytotoxicity of autologous Epstein-Barr virus-transformed cells mediated by interleukin-2 dependent, long-term T cell cultures is augmented by β, but not α, recombinant interferon. J Biol Response Mod 5: 351

    PubMed  Google Scholar 

  7. Chilosi M, Semenzato G, Cetto G, Ambrosetti A, Fiore-Donati L, Perona G, Berton G, Lestani M, Scarpa A, Agostini C, Trentin L, Zambello R, Masciarelli M, Dazzi F, Vinante F, Caligaris-Cappio F, Pizza G (1987) Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia relationship with the effect of recombinant α interferon therapy on clinical parameters and natural killer in vitro activity. Blood 70: 1530

    PubMed  Google Scholar 

  8. Chun M, Hoffmann MK (1987) Modulation of interferon-induced NK cells by interleukin 2 and cAMP. Lymphokine Res 1: 91

    Google Scholar 

  9. D'Atri S, Tentori L, Fuggetta MP, Marini S, Bonmassar E (1986) A miniaturized cell-mediated cytotoxicity assay with human effector mononuclear cells. Int J Tissue React 8: 383

    PubMed  Google Scholar 

  10. Davey FR, Dock NL, Wolos JA (1980) Studies of lymphocyte proliferation in hairy cell leukaemia: activity in mixed lymphocyte reaction and responses to mitogens. Br J Haematol 45: 29

    PubMed  Google Scholar 

  11. Durant JR (1987) Immunotherapy of cancer: the end of the beginning? N Engl J Med 316: 939

    PubMed  Google Scholar 

  12. Eberlein TJ, Rodrick ML, Massaro AF, Jung SE, Mannick JA, Schoof DD (1989) Immunomodulatory effects of systemic lowdose recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Immunol Immunother 30: 145

    PubMed  Google Scholar 

  13. Foa R, Lauria F, Lusso P, Raspadori D, Fierro MT, Tazzari PL, Caudana L, Matera L (1986) Phenotypic and functional characterization of the circulating NK compartment in hairy cell leukaemia. Clin Exp Immunol 64: 392

    PubMed  Google Scholar 

  14. Foa R, Pierro MT, Lusso P, Bonferroni M, Raspadori D, Buzzi M, Zinzani PL, Resegotti L, Lauria F (1987) Effect of α-interferon on the immune system of patients with hairy cell leukemia. Leukemia 1: 377

    PubMed  Google Scholar 

  15. Foon KA, Maluish AE, Abrams PG, Wrightington S, Stevenson HC, Alarif A, Fer MF, Overton WR, Poole M, Schipper EA, Jaffe ES, Herberman RB (1986) Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results. Am J Med 80: 351

    PubMed  Google Scholar 

  16. Knight RA, Worman CP, Cawley JC (1983) Defective autologous and allogeneic mixed lymphocyte reactions in hairy cell leukaemia. Clin Exp Immunol 53: 600

    PubMed  Google Scholar 

  17. Krigel RL, Padavic-Shaller KA, Rudolph AR, Litwin S, Konrad M, Bradley EC, Comis RL (1988) A phase I study of recombinant interleukin 2 plus recombinant β-interferon. Cancer Res 48: 3875

    PubMed  Google Scholar 

  18. Kuribayashi K, Gillis S, Kern DE, Henney CS (1981) Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity. J Immunol 126: 2321

    PubMed  Google Scholar 

  19. Lauria F, Foà R, Matera L, Raspadori D, Tura S (1984) Membrane phenotype and functional behaviour of T lymphocytes in hairy cell leukemia (HCL). Semin Oncol 11: 409

    PubMed  Google Scholar 

  20. Liberati AM, Ballatori E, Fizzotti M, Schippa M, Proietti MG, Di Marzio R, Pecci A, Biscetti L, Sbarretti R, Cini L, Grignani F (1987) Immunologic profile in patients with Hodgkin's disease in complete remission. Cancer 59: 1906

    PubMed  Google Scholar 

  21. Liberati AM, Schippa M, Portuesi MG, Proietti MG, De Angelis V, Ferrajoli A, Cinieri S, Di Clemente F, Palmisano L, Berruto P (1991) IFNβ induced biochemical and immunological modifications in hairy cell leukemia patients. Haematologica 76: 375

    PubMed  Google Scholar 

  22. Liberati AM, Horisberger M, Schippa M, Di Clemente F, Fizzotti M, Filippo S, Proietti MG, Arzano S, Berruto P, Palmisano L, Cinieri S (1991) Biochemical and immunological host responses of hairy cell leukemia patients to IFNβ. Cancer Immunol Immunother 34: 115

    PubMed  Google Scholar 

  23. Nielsen B, Hokland M, Justesen J, Hasselbalch H, Ellegaard J, Hokland P (1989) Immunological recovery and dose evaluation in IFN-α treatment of hairy cell leukemia: analysis, of leukocyte differentiation antigens, NK and 2′, 5′-oligoadenylate synthetase activity. Eur J Haematol 42: 50

    PubMed  Google Scholar 

  24. Parkinson DR (1988) Interleukin-2 in cancer therapy. Semin Oncol 15: 10

    Google Scholar 

  25. Puri RK, Leland P (1991) In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice. Clin Exp Immunol 85: 317

    PubMed  Google Scholar 

  26. Ramsey KM, Dyer D, Stocks N, Djeu JY (1984) Enhancement of natural killer cell activity by interferon and interleukin-2 in human large granular lymphocytes inhibited by cyclosporine. Transplant Proc 16: 1628

    PubMed  Google Scholar 

  27. Reddy MM, Chinoy P, Grieco MH (1984) Differential effects of interferon-α2 and interleukin-2 on natural killer cell activity in patients with acquired immune deficiency syndrome. J Biol Response Mod 3: 379

    PubMed  Google Scholar 

  28. Reittie JE, Gottlieb D, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand AV, Prentice HG, Brenner MK (1989) Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 73: 1351

    PubMed  Google Scholar 

  29. Ruco LP, Procopio A, Maccallini V, Calogero A, Uccini S, Annino L, Mandelli F, Baroni CD (1983) Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. Blood 61: 1132

    PubMed  Google Scholar 

  30. Sabbe LJM, Meijer CJLM, Jansen J (1980) T lymphocyte function in hairy cell leukaemia. Clin Exp Immunol 42: 336

    PubMed  Google Scholar 

  31. SAS Institute Inc. (1993) Release 6.0. Cari publisher, NC, pp 1195–1210

  32. Semenzato G, Pizzolo G, Agostini C, Ambrosetti A, Zambello R, Trentin L, Luca M, Masciarelli M, Chilosi M, Vinante F, Perona G, Cetto G (1986) α-Interferon activates the natural killer system in patients with hairy cell leukemia. Blood 68: 293

    PubMed  Google Scholar 

  33. Sznol M, Mier JW, Sparano J, Gaynor ER, Weiss GR, Margolin KA, Bar MH, Hawkins MJ, Atkins MB, Dutcher JP (1990) A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b. J Biol Response Mod 9: 529

    PubMed  Google Scholar 

  34. Tamura T, Sasaki Y, Shinkai T, Eguchi K, Sakurai M, Fujiwara Y, Nakagawa K, Minato K, Bungo M, Saijo N (1989) Phase I study of combination therapy with interleukin-2 and beta-interferon in patients with advanced malignancy. Cancer Res 49: 730

    PubMed  Google Scholar 

  35. Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, Fefer A (1988) Influence of dose and duration of infusion of inerleukin-2 on toxicity and immunomodulation. J Clin Oncol 6: 669

    PubMed  Google Scholar 

  36. Timonen T, Ortaldo JR, Herberman RB (1981) Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med 153: 569

    PubMed  Google Scholar 

  37. Trentin L, Ambrosetti A, Zambello R, Agostini C, Masciarelli M, Vinante F, Chilosi M, Pizzolo G, Cetto G, Semenzato G (1987) Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: evaluation of cytotoxic events. Leukemia Res 11: 843

    Google Scholar 

  38. Trentin L, Zambello R, Agostini C, Ambrosetti A, Chisesi T, Raimondi R, Bulian P, Pizzolo G, Semenzato G (1990) Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia. Blood 75: 1525

    PubMed  Google Scholar 

  39. Van De Griend RJ, Ronteltap CPM, Gravekamp C, Monnikendam D, Bolhuis RLH (1986) Interferon-β and recombinant IL-2 ean both enhance, but by different pathways, the nonspecific cytolytic potential of T3− natural killer cell-derived clones rather than that of T3+ clones. J Immunol 136: 1700

    PubMed  Google Scholar 

  40. Vose BM, Riccardi C, Bonnard GD, Herberman RB (1983) Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. Regulatory role of interferon on proliferative and cytotoxic precursors. J Immunol 130: 768

    PubMed  Google Scholar 

  41. Weiner LM, Padavic-Shaller K, Kitson J, Watts P, Kriegel RL, Litwin S (1991) Phase I evaluation of combination therapy with interleukin-2 and gamma interferon. Cancer Res 51: 3910

    PubMed  Google Scholar 

  42. Werkmeister JA, Boyd AW, Triglia T, Burns GF (1985) Lymphocytes from patients with hairy cell leukaemia enable the distinction of two separate subpopulations of activated lymphocyte killer cells generated in mixed lymphocyte culture. Clin Exp Immunol 61: 103

    PubMed  Google Scholar 

  43. Yang SC, Grimm EA, Parkinson DR, Carinhas J, Fry KD, Mendiguren-Rodriguez A, Licciardello J, Owen-Schaub LB, Hong WK, Roth JA (1991) Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial. Cancer Res 51: 3669

    PubMed  Google Scholar 

  44. Zaknoen SL, Kay NE (1990) Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Rev 4: 165

    PubMed  Google Scholar 

  45. Ziegler HW, Kay NE, Zarling JM (1981) Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 27: 321

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Policlinico Monteluce, Istituto Medicina Interna e Scienze Oncologiche, Via Bonacci Brunamoni, I-06122, Perugia, Italy

    Anna Marina Liberati, Verena De Angelis, Marco Fizzotti, Monica Schippa, Michela Cecchini, Daniela Adiuto, Francesco Di Clemente & Saverio Cinieri

  2. Indistria Farmaceutica Serono, Roma, Italy

    Lucia Palmisano

  3. Servizio di Medicina Nucleare, Ospedale Civile, Terni, Italy

    Elisabetta Micozzi

  4. Ospedale Civile, Spoleto, Italy

    Massimo Zuccaccia

Authors
  1. Anna Marina Liberati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Verena De Angelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Fizzotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Monica Schippa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michela Cecchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daniela Adiuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francesco Di Clemente
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lucia Palmisano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Elisabetta Micozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Massimo Zuccaccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Saverio Cinieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liberati, A.M., De Angelis, V., Fizzotti, M. et al. Natural-killer-stimulatory effect of combined low-dose interleukin-2 and interferon β in hairy-cell leukemia patients. Cancer Immunol Immunother 38, 323–331 (1994). https://doi.org/10.1007/BF01525511

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01525511

Key words

Search

Navigation